Sign in
Taking people in United StatesPhase 1

CAR T-cell therapy tested in young patients with CD123-positive blood cancers

Tests CD123-targeted CAR T cells in patients up to 21 with relapsed or resistant leukemia.

Key facts

Who runs it
St. Jude Children's Research Hospital
Where
Memphis, United StatesSee the site
Trial code
Registry title
CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)
Status
Recruiting
Phase
Phase 1
People taking part
108 people, planned
Started
29 Jul 2020
Expected to end
29 Jul 2030
Type of study
Interventional, 2 groups
Treatments tested
  • CD123-CAR T
  • Cyclophosphamide
  • Fludarabine
  • Mesna
  • Rituximab
Record updated
19 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people aged 21 or younger whose CD123-positive leukemia (AML/MDS, B-ALL, T-ALL or BPDCN) came back or did not respond to treatment. It tests CD123-CAR T cells.

Age
21 years or younger
Sex
All sexes can join.
Disease stage
CD123-positive AML/MDS, B-ALL, T-ALL or BPDCN that has relapsed or not responded to treatment. For treatment, disease must be detectable (at least MRD+).
Earlier treatment
AML/MDS: relapse after a first complete remission, or no complete remission after 2 cycles of induction chemotherapy. B-ALL: CD19 negative/dim or otherwise unable to have CD19-directed therapy. BPDCN: front-line therapy has failed. After a prior donor stem cell transplant, the person must have recovered, have no active GVHD and no donor lymphocyte infusion in the 28 days before.
Biomarker or test result
The disease must be CD123 positive. For B-ALL, CD19 negative/dim or not able to have CD19-directed therapy.

Main reasons for not taking part

  • Known primary immunodeficiency or history of HIV infection
  • Severe uncontrolled infection
  • Acute promyelocytic leukemia (APL, t(15;17))
  • Active CNS disease
  • Pregnant or breastfeeding

The registry criteria, word for word

Show all 48 criteriaShow less

Who can take part

  • Age ≤21 years old
  • Relapsed/refractory CD123+ disease defined as follows:; AML/MDS
  • Relapsed disease: Patients developing recurrent disease after a first complete remission (CR)
  • Refractory disease: Patients not achieving a CR after 2 cycles of induction chemotherapy; B-cell ALL
  • Relapsed disease that is CD123 positive and CD19 negative/dim or patients otherwise ineligible for CD19 directed therapies including; Patients in 2nd or greater relapse; Patients with relapse after allogeneic HSCT
  • Refractory disease that is CD123 positive and CD19 negative/dim or patients otherwise ineligible for CD19 directed therapies; T-cell All • Relapsed refractory disease that is CD123 positive; BPDCN
  • Relapsed/refractory disease that has failed front-line therapy
  • Estimated life expectancy of >12 weeks
  • Karnofsky or Lansky (age-dependent) performance score ≥50
  • Patients with a history of prior allogeneic HCT must be clinically recovered from prior HCT therapy, have no evidence of active GVHD and have not received a donor lymphocyte infusion (DLI) within the 28 days prior to apheresis
  • Patient must have an identified, suitable HCT donor
  • For females of child-bearing age:
  • Not lactating with intent to breastfeed
  • Not pregnant with negative serum pregnancy test within 7 days prior to enrollment
  • Meets eligibility criteria to undergo autologous apheresis, or have previously undergone autologous apheresis
  • Age≤21 years old
  • Detectable disease that is CD123+ (at least MRD+ disease)
  • Estimated life expectancy of >8 weeks
  • Karnofsky or Lansky (age-dependent) performance score≥50
  • Patients with a history of prior allogeneic HCT must be clinically recovered from prior HCT therapy, have no evidence of active GVHD and have not received a donor lymphocyte infusion (DLI) within the 28 days prior to planned infusion
  • Patient must have an identified, suitable HCT donor
  • Adequate cardiac function defined as left ventricular ejection fraction >40%, OR shortening fraction ≥25%
  • EKG without evidence of clinically significant arrhythmia
  • Adequate renal function defined as creatinine clearance or radioisotope GFR ≥50 ml/min/1.73m2 (GFR ≥40 ml/min/1.73m2 if < 2 years of age)
  • Adequate pulmonary function defined as forced vital capacity (FVC)≥50% of predicted value; or pulse oximetry≥92% on room air if patient is unable to perform pulmonary function testing
  • Total Bilirubin≤3 times the upper limit of normal for age, except in subjects with Gilbert's syndrome
  • Alanine aminotransferase (ALT) OR aspartate aminotransferase (AST) ≤5 times the upper limit of normal for age
  • Has recovered from all NCI CTAE grade III-IV, non-hematologic acute toxicities from prior therapy
  • For females of child-bearing age; Not lactating with intent to breastfeed; Not pregnant with negative serum pregnancy test within 7 days prior to enrollment
  • If sexually active, agreement to use birth control until 3 months after T- cell infusion. Male partners should use a condom
  • Available autologous transduced T-cell product that has met GMP release criteria

Who cannot take part

  • Known contraindication to the protocol defined lymphodepleting chemotherapy regimen of fludarabine/cyclophosphamide
  • Receiving systemic steroids therapy exceeding the equivalent of 0.5 mg/kg/day of methylprednisolone, in the 7 days prior to CD123-CAR T- cell infusion
  • Receiving systemic therapy in the 14 days prior to CD123-CAR T-cell infusion, which will interfere with the activity of the CD123-CAR T cells in vivo (in the opinion of the study PI(s))
  • Receiving rituximab therapy in the 30 days prior to CD123-CAR T cell infusion. (This exclusion criterion is intended to prevent premature exposure of CD123-CAR T cells to rituximab, which would activate the safety switch and promote CAR T-cell apoptosis)
  • Receiving intrathecal chemotherapy in the 7 days prior to CD123-CAR T cell infusion
  • Known contraindication to the protocol defined lymphodepleting chemotherapy regimen of fludarabine/cyclophosphamide
  • History of HIV infection
  • Severe intercurrent uncontrolled bacterial, viral or fungal infection (e.g. active hepatitis B or C infection or adenovirus infection)
  • History of hypersensitivity reactions to murine protein-containing products
  • History of HIV infection
  • Severe intercurrent uncontrolled bacterial, viral or fungal infection
  • History of hypersensitivity reactions to murine protein-containing products
  • History of severe hypersensitivity reactions to cornstarch or hydroxyethyl starch
  • Active CNS disease
  • Known primary immunodeficiency
  • Patients with acute promyelocytic leukemia (APL, t (15;17))
  • Known primary immunodeficiency

Where in United States

  • St. Jude Children's Research HospitalMemphis, United StatesContact: Swati Naik, MDTaking people

About the trial

What the trial wants to find out

The CD123-CAR T-cell therapy is a new treatment that is being investigated for treatment of AML/myelodysplastic syndrome (MDS), T- or B- acute lymphoblastic leukemia (ALL) or blastic plasmacytoid dendritic cell neoplasia (BPDCN). The purpose of this study is to find the maximum (highest) dose of CD123-CAR T cells that is safe to give to these patients. This would include studying the side effects of the chemotherapy, as well as the CD123-CAR T-cell product on the recipient's body, disease and overall survival.

Read full original descriptionShow less

Primary Objective:

* To determine the safety of one intravenous infusion of escalating doses of autologous, CD123-CAR T cells in patients (≤21 years) with recurrent/refractory CD123+ disease (AML/MDS, B-ALL, T-ALL or BPDCN) after lymphodepleting chemotherapy. * To determine the safety of an intravenous infusion of escalating doses of donor derived, CD123-CAR T cells in patients (≤21 years) with recurrent/refractory CD123+ disease (AML/MDS, B-ALL, T-ALL, BPDCN or MPAL) after lymphodepleting chemotherapy.

Secondary Objectives

- To evaluate the antileukemia activity of CD123-CAR T cells.

Exploratory Objectives

* To assess the immunophenotype, clonal structure and endogenous repertoire of CD123-CAR T cells and unmodified T cells * To characterize the cytokine profile in the peripheral blood and CSF after treatment with CD123-CAR T cells * To characterize tumor cells post CD123-CAR T-cell therapy * To compare in vivo properties of donor-derived versus autologous CD123- CAR T cells

The 2 groups in the trial

  • ARM A CD123-CAR T cell therapyOther group

    For patients who have not received an allogeneic transplant or for patients who have received allogeneic transplant and do not have a transplant donor available CD123-CAR T-cell dose and infusion Up to 4 Dose levels will be evaluated with a maximum dose of 2.5 x 10\^8 CAR+ T cells. If dose limiting toxicities (DLTs) are observed on Dose level 1 then the cell dose is de- escalated.

    Treatment: CD123-CAR T, Cyclophosphamide, Fludarabine, Mesna, and Rituximab

  • ARM B CD123-CAR T cell therapyTreatment being tested

    For patients who relapsed following allogeneic transplant and whose CAR T-cells will be manufactured from the previous transplant donor, when available. CD123-CAR T-cell dose and infusion Up to 4 Dose levels will be evaluated with a maximum dose of 2.5 x 10\^8 CAR+ T cells. If dose limiting toxicities (DLTs) are observed on Dose level 1 then the cell dose is de- escalated.

    Treatment: CD123-CAR T, Cyclophosphamide, Fludarabine, Mesna, and Rituximab

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)
Plain-language title
CAR T-cell therapy tested in young patients with CD123-positive blood cancersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
19 May 2026